The team

Cerapedics is a passionate, customer-focused, research-based team

The Cerapedics team is dedicated to enhancing the science of bone repair by staying at the leading edge of osteobiologic science and product development.

To find out more about the Cerapedics Board and Leadership Team, please see below.

The Board

Anthony Koblish

Antony Koblish

Anthony Koblish is a medical device entrepreneur with 25 years of experience who has served on the Cerapedics board of directors since 2013. He is currently co-founder, president and CEO of TELA Bio, a biosurgical reconstruction company. Prior to founding TELA Bio, Mr. Koblish was president and CEO of Orthovita, a publicly traded orthobiologics and biosurgery medical device company, where he helped grow the company’s valuation from $30 million to a $316 million sale to Stryker Corporation.

Kenneth Abramowitz

Kenneth Abramowitz

Kenneth Abramowitz is a co-founder and Managing General Partner of NGN Capital. He joined NGN Capital from The Carlyle Group in New York where he was Managing Director from 2001 to 2003, focused on U.S. buyout opportunities in the healthcare industry. Beginning July 2003, he transitioned to Senior Advisor at Carlyle in order to devote the time necessary to create a dedicated healthcare fund on behalf of Carlyle. Prior to joining Carlyle, Mr. Abramowitz worked as an Analyst at Sanford C. Bernstein & Co. where he covered the medical-supply, hospital-management and HMO industries for 23 years, after which he was an EGS Securities Healthcare Fund Manager. He was voted top hospital supply and/or service analyst on the Institutional Investor Magazine “All-America Research Team” during 15 out of 20 years between 1980-2000 and made “The Team” for both healthcare services and medical supplies for 9 years since 1987.

Douglas Kohrs

Douglas Kohrs

Douglas Kohrs has 35 years of experience in the medical device industry as a founder, board member, and executive of many innovative companies and non-profit organizations. He is currently managing director of Responsive Arthroscopy, a company focused on value-based healthcare solutions for sports medicine. Prior to Responsive Arthroscopy, Mr. Kohrs founded Responsive Orthopedics, which was acquired by Medtronic in 2016. He also has served as president and CEO of both organizations. He currently serves on the board of directors of six entities and is the president of the Foundation for Essential Needs, a non-profit focused on eradicating hunger.

Valeska Schroeder

Valeska Schroeder

Valeska has served as our Chief Executive Officer since late 2022 and as Chairman of the Board since late 2021. Prior to assuming the role of CEO, Valeska served as a Managing Director of KCK, a single-family evergreen fund that invests in industries, including medical technologies. Since 2016, Valeska was part of KCK’s Medical Technologies Investment Group, where she was responsible for leading investments and advising portfolio companies. Valeska has been a board member for KCK portfolio companies, including Cerapedics, Sight Sciences, Aerin Medical, Intuity Medical, and Lungpacer. Before joining KCK, Valeska held roles in product development, program management, and marketing in a number of medical device companies. Valeska obtained a BS, MS, and PhD from University of California at Berkeley in Materials Science and Engineering.

Greg Garfield

Greg Garfield

Greg Garfield currently serves as Head of Medical Technology Investments for the KCK Group. Previously, Greg was the General Manager of Laryngology and Emerging Therapies for J&J’s Acclarent subsidiary, which J&J purchased for $800M. Prior to this role, Greg served as Acclarent’s Chief Operating Officer focusing on developing and commercializing products for use by ENT physicians to improve and enhance patients’ lives. Greg has many years of experience in the medical technology industry in a variety of roles.

Andrew Tofe

Andrew Tofe, PHD

Andrew Tofe, PhD has over forty years of experience in developing and commercializing diagnostic and therapeutic products for bone disease and bone repair. This research and work in bone includes over 50 publications and patents. Dr. Tofe founded and served as President and Chief Executive Officer of CeraMed Dental, where he developed and brought to market three different types of bone substitutes, OsteoGraf®/N in 1990, OsteoGraf®/LD in 1994, PepGen P-15™ in 1999, and PepGen P-15 Flow in 2001. Dr. Tofe served as President and Chief Executive Officer from the transition of CeraMed Dental into Cerapedics, Inc until 2006.

Tyrell Rivers

Tyrell Rivers

Tyrell J. Rivers, Ph.D., has served as a member of the board of directors of Cerapedics since June 2018. Dr. Rivers is also an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for equity investments, mergers and acquisitions, and divestments. Prior to this role, Dr. Rivers was at MedImmune Ventures where he specialized in biotechnology investing, and at Merck & Co., Inc. where he led the technical support for multiple commercial vaccine franchises and subsequently directed global business initiatives for accessing key technologies for research and development. Dr. Rivers earned his BS in Chemical Engineering from the Massachusetts Institute of Technology, a PhD in Chemical Engineering from University of Texas at Austin, and his MBA from the New York University Stern School of Business. Dr. Rivers serves on the board of directors for ADC Therapeutics SA, Armaron Bio Ltd, Corvidia Therapeutics and Viela Bio, Inc. and previously G1 Therapeutics, Inc. (GTHX) and PhaseBio Pharmaceuticals, Inc. (PHAS). He also serves as a board observer for several private companies.

Nael Kassar

Nael Kassar

Leadership

Valeska Schroeder

Valeska Schroeder

CEO

Valeska has served as our Chief Executive Officer since late 2022 and as Chairman of the Board since late 2021. Prior to assuming the role of CEO, Valeska served as a Managing Director of KCK, a single-family evergreen fund that invests in industries, including medical technologies. Since 2016, Valeska was part of KCK’s Medical Technologies Investment Group, where she was responsible for leading investments and advising portfolio companies. Valeska has been a board member for KCK portfolio companies, including Cerapedics, Sight Sciences, Aerin Medical, Intuity Medical, and Lungpacer. Before joining KCK, Valeska held roles in product development, program management, and marketing in a number of medical device companies. Valeska obtained a BS, MS, and PhD from University of California at Berkeley in Materials Science and Engineering. 

Jeffrey G. Marx, Ph.D.

Jeffrey G. Marx, Ph.D.

President & COO

Jeffrey Marx serves as President & Chief Operating Officer, overseeing regulatory, quality, manufacturing, and R&D efforts for the company. With some two decades of experience in executive management with medical device companies, he brings considerable expertise in research & development, commercialization, sales management, business development and strategic planning. His experience includes over 13 years with Orthovita, where he was VP Corporate Development. When Orthovita was acquired by Stryker Orthobiologics, Jeff led the team that integrated the two companies; he continued as VP Corporate Development at Stryker. He has earned a Ph.D. in Ceramic Engineering from Missouri University of Science and Technology, Rolla MO.

Ajay Bansal

Ajay Bansal

CFO

Ajay has been a healthcare CFO over the last almost 20 years. He has served as a CFO for several biotech and medtech companies including Nektar Therapeutics, Tercica, Complete Genomics, Onconova, ViewRay, Urovant, and Truvian Sciences. He led IPOs at Complete and Onconova and M&A exits at Tercica, Complete, and Urovant. He also spent many years as CFO of ViewRay, a commercial-stage, publicly traded medtech company. Prior to his CFO roles, he served as a consultant (ZS, McKinsey), in various functional roles at Novartis, and as a Partner with Mehta Partners. Ajay received his B. Tech in Mechanical Engineering from IIT, Delhi, his masters in Operations Research from Northwestern University, and his M.B.A. degree from Kellogg Graduate School of Management.

matt_thomas

Matt Thomas

CCO

Matt Thomas has over 25 years of experience leading medical device businesses.  He has broad experience in strategy, business development, marketing, sales & new product development.  Prior to joining Cerapedics in 2020, Matt was Vice President & General Manager for Medtronic’s Spinal Cord Stimulation & Early Interventions pain business.  Previously, Matt also led a turnaround of Medtronic’s Kyphon business, returning it to growth for the first time since the acquisition.  He joined Medtronic in 2002 and also had leadership roles in spine, diabetes, and deep brain stimulation.  Prior to Medtronic, he was a product manager with Sonic Innovations and founder of HyperX, a health care data services company.  He has an MBA from Carnegie Mellon University, a BS in economics from the University of Utah and studied at Johns Hopkins University.

Brice Johnson

Brice Johnson

VP of Human Resources

Brice Johnson is a senior Human Resources leader with over 20 years of progressive HR experience. He has successfully managed human capital & led HR teams in Fortune 150, mid-size, & entrepreneurial organizations across varied industries including medical device, pharmaceutical, CPG/food, healthcare, animal health, & higher education.  He has broad experience aligning business and HR strategy with talent ensuring that the required structure, capabilities, culture, and leadership are developed and in place to achieve business and growth objectives.  Prior to joining Cerapedics, Brice held HR leadership positions with several companies including LivaNova and Eli Lilly and Company. Brice earned his Bachelor of Chemical Engineering degree from Georgia Institute of Technology.

Kimberly Burke

Kimberly Burke

General Counsel

Kimberly Burke has over 20 years’ experience in corporate governance, securities law and compliance matters, focusing on companies in the life sciences sector. Before joining Cerapedics in 2022, she served as Senior Vice President, Deputy General Counsel of Novocure, a publicly traded global oncology company.  Prior to that, Kimberly was General Counsel and Chief Compliance Officer of Echo Therapeutics, a publicly traded company developing a non-invasive continuous glucose monitor, where she also served as Interim CEO. She also served as Associate General Counsel for Cato Research, a global contract research organization, among other legal roles where she advised public and private companies on strategic, corporate governance, securities and other legal matters . Kimberly received her J.D. from the College of William and Mary, School of Law and her B.A. in English and Political Science from Mount Holyoke College.